Ahmed M. Abdelhady - Concepedia

Author

Ahmed M. Abdelhady

Also Known As

A. Abdel-Hady, A. Abdelhady, A. M. Abdelhady, A.M. Abdelhady, Ahmed Abdel-Hady, Ahmed Abdelhady, Ahmed M Abdelhady, Ahmed M. Abdelhady, ahmed abdelhady

Publications

367

Citations

H-Index

Concepts

All Affiliations

Novartis (Switzerland)University of Chicago Novartis (United States)Medical University of Vienna Hôpital Maisonneuve-Rosemont

About

Ahmed M. Abdelhady is an author at Novartis (Switzerland) specializing in medicine, cancer research, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	45
2	Health Sciences	2	2	26
3	Immunology	2	2	26
4	Cellular Therapies	1	1	11
5	Marrow Transplantation	1	1	11

Ahmed M. Abdelhady

Publications

307

Citations

H-Index

Page 1

	Year	Citations
CRISPR-Cas9 In Vivo Gene Editing of <i>KLKB1</i> for Hereditary Angioedema Hilary Longhurst, Karen Lindsay, Remy S. Petersen, New England Journal of Medicine	2024	142
CRISPR-Based Therapy for Hereditary Angioedema Danny M. Cohn, Padmalal Gurugama, Markus Magerl, New England Journal of Medicine	2024	36
Losartan may inhibit the progression of liver fibrosis in chronic HCV patients Zakaria A. Salama, Ahmed Sadek, Ahmed M. Abdelhady, HepatoBiliary Surgery and Nutrition	2016	31
Portia: A Phase 1b Study Evaluating Safety and Efficacy of Tisagenlecleucel and Pembrolizumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Ulrich Jaeger, Nina Worel, Joseph P. McGuirk, Blood	2019	21
Evaluation of Absolute Oral Bioavailability and Bioequivalence of Ribociclib, a Cyclin‐Dependent Kinase 4/6 Inhibitor, in Healthy Subjects Yan Ji, Ahmed M. Abdelhady, Tanay S. Samant, Clinical Pharmacology in Drug Development OncologyHealthy SubjectsPharmacological Study600-Mg Ribociclib TabletRibociclib 600-Mg Capsule	2020	19
Efficacy and safety of tisagenlecleucel (Tisa-cel) in adult patients (Pts) with relapsed/refractory follicular lymphoma (r/r FL): Primary analysis of the phase 2 Elara trial. Stephen J. Schuster, Michael Dickinson, Martin Dreyling, Journal of Clinical Oncology ImmunologyImmunotherapyOncologyComplete Response RateHematology	2021	15
Phase Ib/II study of ceritinib in combination with ribociclib in patients with ALK-rearranged non–small cell lung cancer Armando Santoro, Wu‐Chou Su, Alejandro Navarro, Lung Cancer	2022	12
Safety and efficacy of tisagenlecleucel (tisa-cel) plus pembrolizumab (pembro) in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): Updated analysis of the phase 1b PORTIA study. Ulrich Jäger, Nina Worel, Joseph P. McGuirk, Journal of Clinical Oncology Cell TherapyR/r DlbclImmunologyPathologyImmunotherapy	2021	11
Expression of ERG Protein and TMRPSS2-ERG Fusion in Prostatic Carcinoma in Egyptian Patients Ahmed M. Abdelhady, Ali El‐Hindawi, Olfat Hammam, Open Access Macedonian Journal of Medical Sciences	2017	10
Inactivation of MS2 bacteriophage on copper film deployed in high touch areas of a public transport system Manuel Monge, Ahmed M. Abdelhady, Lola Denise Aslett, Letters in Applied Microbiology	2021	10

Page 1